Search

Meeting Coverage:

American Academy of Ophthalmology

AAO: 2018

Take-Home Points for APL-2

David S. Boyer, MD

Show Description +

David S. Boyer, MD, shares 18-month data from the phase 2 trial (FILLY) of the APL-2 complement C3 inhibitor (Apellis Pharmaceuticals). This study assessed the safety and efficacy of the compound in the treatment of geographic atrophy in patients with age-related macular degeneration.

Posted: 10/26/2018

Keywords:

Age-Related Macular Degeneration (AMD)

•

Geographic Atrophy (GA)

•

Retina Subspecialty Day

Up Next

$A Revolution in Imaging Technology for Corneal and Refractive Surgery$

A Revolution in Imaging Technology for Corneal and Refractive Surgery

Renato Ambrósio Jr, MD, PhD

Customizing the IOL

Customizing the IOL

George O. Waring IV, MD, FACS

Anatomy in HAWK and HARRIER

Anatomy in HAWK and HARRIER

Pravin U. Dugel, MD

All About the Jacob Paperclip Capsule Stabilizer

All About the Jacob Paperclip Capsule Stabilizer

Soosan Jacob, MS, FRCS, DNB

Phase 3 CEDAR and SEQUOIA Clinical Trial Results

Phase 3 CEDAR and SEQUOIA Clinical Trial Results

Rahul N. Khurana, MD

Surgical Pearls for Angle Closure Patients

Surgical Pearls for Angle Closure Patients

Steven Vold, MD

New IOL Technologies

New IOL Technologies

Amr M. Kouchouk, MD, Kendall E. Donaldson, MD, MS, Vance M. Thompson, MD, FACS

The Art and Science of YAG Vitreolysis

The Art and Science of YAG Vitreolysis

Chirag P. Shah, MD, MPH

Topical Retina Treatments

Topical Retina Treatments

Carl D. Regillo, MD, FACS, Caroline R. Baumal, MD, Michael A. Singer, MD

Follow-up on the SMILE Procedure

Follow-up on the SMILE Procedure

Osama Ibrahim, MD

Takeaways From New STAIRWAY Study Data

Takeaways From New STAIRWAY Study Data

Arshad Khanani, MD

$Refractive Residencies$

Refractive Residencies

George O. Waring IV, MD, FACS , Osama Ibrahim, MD, Renato Ambrosio Jr, MD, PhD

Back to All Videos

Take-Home Points for APL-2

David S. Boyer, MD

David S. Boyer, MD, shares 18-month data from the phase 2 trial (FILLY) of the APL-2 complement C3 inhibitor (Apellis Pharmaceuticals). This study assessed the safety and efficacy of the compound in the treatment of geographic atrophy in patients with age-related macular degeneration.

Posted: 10/26/2018

Keywords:

Age-Related Macular Degeneration (AMD)

•

Geographic Atrophy (GA)

•

Retina Subspecialty Day

Please log in to leave a comment.

More From AAO: 2018 Coverage

Anatomy in HAWK and HARRIER

Anatomy in HAWK and HARRIER

Pravin U. Dugel, MD

All About the Jacob Paperclip Capsule Stabilizer

All About the Jacob Paperclip Capsule Stabilizer

Soosan Jacob, MS, FRCS, DNB

Phase 3 CEDAR and SEQUOIA Clinical Trial Results

Phase 3 CEDAR and SEQUOIA Clinical Trial Results

Rahul N. Khurana, MD

Surgical Pearls for Angle Closure Patients

Surgical Pearls for Angle Closure Patients

Steven Vold, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2018.